The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical analysis of 34 cases of primary non-Hodgkin lymphoma of breast
Pages: 596-600
Year: Issue:  5
Journal: Oncology Progress

Abstract: Objective To assess the clinicopathological features, treatment regimens and prognostic factors of prima-ry non-Hodgkin's lymphoma of breast (PNHLB). Method The clinical data of thirty-four inpatients with PNHLB were enrolled, and the clinicopathological features, treatment regimens and survival time were retrospectively analyzed through telephone and clinical follow-up. Result All of the 34 cases were female, and the median age was 46. 19 cases (56%) were at phase Ⅰ, 8 cases (24%) at phase Ⅱ, only one case (3%) at phase Ⅲ, and 6 cases (18%) at phase Ⅳ. Ki-67, Bcl-2, CD10, Bcl-6 and Mum-1 were observed by immunohistochemical detection in some of the cases. Treatment regi-mens included surgery alone (2 cases), surgery+chemotherapy (14 cases), surgery+chemoradiotherapy (7 cases), che-motherapy+radiotherapy (4 cases), Rituximab in combination (22 cases), preventive intrathecal injection in combination (2 cases) and hematopoietic stem cell transplantation (3 cases). The duration of follow-up was 0.5 to 149.0 months, 8 pa-tients died. The median OS was not reached, and the median PFS was 86.0 months (95%CI=16.1-155.9 months). The 1-, 2-, 3-and 5-year overall survival rates were 90.3%, 87.0%, 83.6%and 73.3%, respectively;the progression-free survival rates were 75.1%, 61.5%, 61.5%and 51.0%, respectively. Results of Log-rank univiarate analysis showed that, the prima-ry site of the tumor, clinical stage and IPI score were related to median OS;whether CR were reached after treatment and IPI score were related to median PFS. Conclusion PNHLB tends to be of B-cell origin, with the majority being diffuse large B cell lymphoma (DLBCL). At present, the main treatment mode for PNHLB is surgery combined with radiothera-py, chemotherapy and Rituximab targeted therapy. CHOP is the main chemotherapy regimen, and preventive intrathecal injection may improve patient survival.
Related Articles
No related articles found